Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Retained Earnings: 2023-2024

Historic Retained Earnings for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to -$218.0 million.

  • CG Oncology's Retained Earnings fell 81.36% to -$337.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$337.7 million, marking a year-over-year decrease of 81.36%. This contributed to the annual value of -$218.0 million for FY2024, which is 67.75% down from last year.
  • Per CG Oncology's latest filing, its Retained Earnings stood at -$218.0 million for FY2024, which was down 67.75% from -$129.9 million recorded in FY2023.
  • CG Oncology's 5-year Retained Earnings high stood at -$129.9 million for FY2023, and its period low was -$218.0 million during FY2024.
  • Moreover, its 2-year median value for Retained Earnings was -$174.0 million (2023), whereas its average is -$174.0 million.
  • Data for CG Oncology's Retained Earnings shows a maximum YoY crashed of 67.75% (in 2024) over the last 5 years.
  • Over the past 2 years, CG Oncology's Retained Earnings (Yearly) stood at -$129.9 million in 2023, then tumbled by 67.75% to -$218.0 million in 2024.